Physician profile
Adil Sattar
NPI 1235440652
$5,733.46
in general payments reported to CMS, 2019-2025
23 companies · $871 in 2025
The $871 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $17.80 · 2021: $464 · 2022: $1,605 · 2023: $680 · 2024: $1,986 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Travel and Lodging: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.99 |
| Travel and Lodging | $1,363.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,252.19 | 2021-2022 | |
| Boston Scientific Corporation | $1,251.82 | 2024-2025 | Versacross Access Solution, Watchman Flx, Bodyguardian |
| Medtronic, INC. | $1,176.83 | 2021-2025 | Corevalve Evolut R, Venaseal |
| E.R. Squibb & Sons, L.L.C. | $352.88 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $267.72 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $265.86 | 2024-2025 | |
| Pfizer INC. | $244.78 | 2022-2025 | |
| Biotronik INC. | $167.88 | 2022 | |
| Amgen INC. | $114.15 | 2023-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $102.90 | 2019 | |
| Novo Nordisk INC | $100.21 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Actelion Pharmaceuticals US, INC. | $91.41 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $80.59 | 2021-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Angiodynamics, INC. | $46.52 | 2025 | Alphavac |
| Astrazeneca Pharmaceuticals LP | $44.13 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $37.19 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.08 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $28.09 | 2023 | |
| Chiesi USA, INC. | $22.05 | 2025 | Kengreal |
| Irhythm Technologies, INC. | $17.65 | 2024 | Zio At Patch |
| Philips North America LLC | $17.27 | 2025 | Coronary Other |
| Bayer Healthcare Pharmaceuticals INC. | $15.08 | 2025 | |
| Cardiovascular Systems INC. | $6.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Sattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.